ARTICLE | Company News
BeiGene, Ambrx partner to discover, develop cancer biologics
March 8, 2019 5:30 PM UTC
BeiGene partnered with Ambrx to discover cancer therapeutics using the latter's site-specific conjugation technology.
The technology uses cell lines engineered with transfer RNAs (tRNAs)/tRNA synthase that can incorporate non-natural amino acids into specified peptide and protein sites during translation. The amino acids are chemically modified to add functionality and enhance activity...